CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results
10 janv. 2022 08h00 HE
|
CVRx, Inc.
MINNEAPOLIS, Jan. 10, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2
04 janv. 2022 08h30 HE
|
ARCA biopharma, Inc.
Clinically important bradycardia is common in heart failure (HF) patients with persistent or paroxysmal atrial fibrillation (AF)In a Phase 2B clinical trial, the prevalence of clinically important...
DAXOR AWARDED NEW PATENT FOR BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES
04 janv. 2022 08h00 HE
|
Daxor Corporation
Method Patent Covers Blood Volume Analysis Technology to Evaluate and Guide Treatment Decisions in Multiple Medical Conditions Oak Ridge, TN, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation...
CVRx to Present at the 40th Annual J.P. Morgan Healthcare Conference
21 déc. 2021 16h05 HE
|
CVRx, Inc.
MINNEAPOLIS, Dec. 21, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference
16 nov. 2021 16h05 HE
|
CVRx, Inc.
MINNEAPOLIS, Nov. 16, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally...
Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)
08 nov. 2021 07h00 HE
|
Imara, Inc.
Preclinical data from three different mouse models of HFpEF to be presented at American Heart Association (AHA) Scientific Sessions HFpEF development to be led by cardiologist Toni Bransford, M.D.,...
CVRx Reports Third Quarter 2021 Financial and Operating Results
04 nov. 2021 16h05 HE
|
CVRx, Inc.
MINNEAPOLIS, Nov. 04, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and...
Retrospective Analysis Using the VoluMetrix NIVA|HF Investigational Algorithm to Assess Patients With Heart Failure Predicts Hospitalization
04 nov. 2021 09h00 HE
|
VoluMetrix
NASHVILLE, Tenn., Nov. 04, 2021 (GLOBE NEWSWIRE) -- VoluMetrix, a Nashville-based biotech startup dedicated to creating a new wave of solutions for vital monitoring to enhance well-being, today...
CVRx to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call
21 oct. 2021 16h05 HE
|
CVRx, Inc.
MINNEAPOLIS, Oct. 21, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally...
Emerging Drugs for the Heart Failure Treatment: A Focus on Recent Clinical Trials | DelveInsight
19 oct. 2021 20h00 HE
|
DelveInsight Business Research LLP
Los Angeles, USA, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Emerging Drugs for the Heart Failure Treatment: A Focus on Recent Clinical Trials | DelveInsight The pipeline of Heart failure is robust, with...